TARRIFF SCOTT (CEO) sold 3.4% of their position (20.25K shares) of EAGLE PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $300.0K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 10/4/2023ACC: 0001209191-23-052030
DirectorOfficer· CEO
Since Jun 2018
-20.25K
Net shares
Net seller
$300.0K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
20.25K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−9.51K
Price / share
$15.23
Trade value
$144.85K
% of position
1.6%
10/2/2023
587.31K→577.80K
Common Stock
Direct
Shares
−10.02K
Price / share
$14.41
Trade value
$144.45K
% of position
1.7%
10/3/2023
577.80K→567.78K
Common Stock
Direct
Shares
−710.00
Price / share
$15.11
Trade value
$10.73K
% of position
0.1%
10/3/2023
567.78K→567.07K
Total
Net shares
−20.25K
Net value
-$300.03K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 10/2/2023 | S · Sale | −9.51K | $15.23 | $144.85K | 1.6% | 587.31K | 577.80K |
| Common Stock Direct | 10/3/2023 | S · Sale | −10.02K | $14.41 | $144.45K | 1.7% | 577.80K | 567.78K |
| Common Stock Direct | 10/3/2023 | S · Sale | −710.00 | $15.11 | $10.73K | 0.1% | 567.78K | 567.07K |
| Total | −20.25K | -$300.03K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned992.62K
Total
992.62K indirect992.62K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 992.62K | Indirect |
| Total | 992.62K | 992.62K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported